氯巴赞治疗难治性癫痫的加拿大经验。一项回顾性研究。加拿大Clobazam合作集团。

文章的细节

引用

复制到剪贴板

作者不明

氯巴赞治疗难治性癫痫的加拿大经验。一项回顾性研究。加拿大Clobazam合作集团。

癫痫症。1991 5 - 6;32(3):407-16。

PubMed ID

2044502 (查看PubMed

］

摘要

在过去的7年里，在加拿大，有超过1300名难治性癫痫患者接受了104名成人和儿童神经学家的氯巴坦(CLB)治疗。使用一份标准病例报告，32名神经学家(每人治疗过或等于10名患者)提供了877名患者的回顾性数据。该人口具有以下特点;儿童和成人的比例分别为51%和49%;38%的患者为智障;单一发作型和多重发作型疾病的比例分别为46%和54%;成年人有更复杂的部分癫痫发作，而儿童有更多的非典型缺失和肌阵挛类型。在氯巴赞之前，患者平均服用2种其他抗癫痫药物(范围0-5种)。儿童CLB的平均剂量为0.87 mg/kg /天(范围为0.05-3.8 mg/kg /天)，成人为30 mg/天(范围为2.5-150 mg/天)。CLB治疗的持续时间从几天到超过4年，其中40%的治疗时间超过1年。 Using Kaplan-Meier curves, we found that 4 years after starting, 40-50% of patients continued CLB. More than 40% of patients with single seizure type had at least a 50% reduction in seizure frequency (improved). At least 60% of patients with multiple seizure type had improvement in one or more seizure types, and nearly 40% of the patients had all their seizure types improved. The seizure frequency for each seizure type, except tonic, was reduced greater than 50% in 40-50% of patients and by 100% in 10-30% of patients. Twenty percent stopped CLB for poor efficacy, 4% stopped for safety-related reasons including drug interactions, and 8% stopped for both reasons. Possible side effects (predominantly somnolence) were reported by 32%; however, in only 11% were the side effects sufficiently severe to cause discontinuation of medication. "Tolerance," leading to discontinuation of CLB, was reported for 9%. Patients treated with CLB for at least 1 year were generally maintained with CLB greater than 1 year. Thus, CLB is useful in refractory epilepsy of all types, suggesting that a monotherapy trial in less severe epilepsy is now desirable.

引用本文的药库数据

药物

Clobazam